Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Anemia
Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Prolymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Thrombocytopenia

Interventions: Drug: Alvocidib Hydrochloride
Drug: Lenalidomide
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis

First Posted Date: 2008-08-15

Last Posted Date: 2015-04-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00735930

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma
Plasma Cell Neoplasm

Interventions: Drug: lenalidomide
Drug: vorinostat

First Posted Date: 2008-08-07

Last Posted Date: 2020-05-18

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 19

Registration Number: NCT00729118

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States

RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: RAD001
Drug: lenalidomide

First Posted Date: 2008-08-07

Last Posted Date: 2014-08-11

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 28

Registration Number: NCT00729638

Locations: 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 2 locations

Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2008-08-04

Last Posted Date: 2019-01-22

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 42

Registration Number: NCT00727415

Locations: 🇮🇹
Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST, Meldola, Italy
🇮🇹
Unità Operativa Ematologia 1 - Università degli Studi di Bari, Bari, Italy
🇮🇹
Istituto di Ematologia e Oncologia Medica "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi, Bologna, Italy

and more 20 locations

Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone
Drug: Doxil

First Posted Date: 2008-07-29

Last Posted Date: 2017-06-02

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 74

Registration Number: NCT00724568

Locations: 🇺🇸
Dana Farber Cancer Institute (and Massachusetts General), Boston, Massachusetts, United States
🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

and more 3 locations

Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes
Acute Myelogenous Leukemia

Interventions: Drug: lenalidomide

First Posted Date: 2008-07-23

Last Posted Date: 2013-09-27

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 10

Registration Number: NCT00720850

Locations: 🇩🇪
Universitätsklinikum Hamburg-Eppendorf, Onkologisches Zentrum, Hamburg, Germany
🇩🇪
Dresden University of Technology, Medizinische Klinik und Poliklinik 1, Dresden, Saxony, Germany
🇩🇪
Universitätsklinikum Düsseldorf, Medizinische Klinik und Poliklinik, Klinik für Hämatologie, Onkologie und klinische Immunologie, Düsseldorf, Germany

and more 4 locations

Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial

Phase 2

Completed

Conditions: Liver Cancer

Interventions: Drug: lenalidomide

First Posted Date: 2008-07-17

Last Posted Date: 2020-02-17

Lead Sponsor: Brown University

Target Recruit Count: 41

Registration Number: NCT00717756

Locations: 🇺🇸
Memorial Hospital of Rhode island, Pawtucket, Rhode Island, United States
🇺🇸
Lifespan Hospitals, Providence, Rhode Island, United States
🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas

Early Phase 1

Terminated

Conditions: Peripheral T-cell Lymphomas
Adult T-cell Leukemia
Adult T-cell Lymphoma
Peripheral T-cell Lymphoma Unspecified
Angioimmunoblastic T-cell Lymphoma
Anaplastic Large Cell Lymphoma
T/Null Cell Systemic Type
Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease

Interventions: Drug: Lenalidomide

First Posted Date: 2008-06-25

Last Posted Date: 2012-04-20

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 1

Registration Number: NCT00704691

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

Phase 1

Terminated

Conditions: Non-deletion 5q
Myelodysplastic Syndrome
Low to Intermediate-1 MDS
MDS

Interventions: Drug: Lenalidomide

First Posted Date: 2008-06-18

Last Posted Date: 2025-05-04

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 8

Registration Number: NCT00699842

Locations: 🇺🇸
Associates in Hematology-Oncology, PC, Chester, Pennsylvania, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma

Phase 1

Completed

Conditions: Myeloma

Interventions: Drug: Lenalidomide
Biological: Monocyte derived DCs loaded with KRN7000

First Posted Date: 2008-06-17

Last Posted Date: 2016-06-21

Lead Sponsor: Yale University

Target Recruit Count: 6

Registration Number: NCT00698776

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy